|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-7-31
|
|
pubmed:abstractText |
To determine the maximum tolerated dose (MTD) of paclitaxel given as a 96-hour continuous infusion during Weeks 1 and 5 of an accelerated radiotherapy schedule for the definitive treatment of advanced (nonmetastatic) unresectable squamous cell carcinoma of the head and neck (SCCHN).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
311-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10760424-Aged,
pubmed-meshheading:10760424-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10760424-Carcinoma, Squamous Cell,
pubmed-meshheading:10760424-Combined Modality Therapy,
pubmed-meshheading:10760424-Disease Progression,
pubmed-meshheading:10760424-Disease-Free Survival,
pubmed-meshheading:10760424-Dose Fractionation,
pubmed-meshheading:10760424-Drug Administration Schedule,
pubmed-meshheading:10760424-Drug Eruptions,
pubmed-meshheading:10760424-Female,
pubmed-meshheading:10760424-Head and Neck Neoplasms,
pubmed-meshheading:10760424-Humans,
pubmed-meshheading:10760424-Male,
pubmed-meshheading:10760424-Middle Aged,
pubmed-meshheading:10760424-Neutropenia,
pubmed-meshheading:10760424-Paclitaxel,
pubmed-meshheading:10760424-Radiation-Sensitizing Agents,
pubmed-meshheading:10760424-Stomatitis
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer.
|
|
pubmed:affiliation |
Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104, USA. machtay@xrt.upenn.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
